Menlo Therapeutics Receives FDA Approval of ZILXI (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea   #stocks #stockmarket #investing #trading #stockmarketnews #news #stocktrading #Canada #Questrade trade mark